Peter Winkle

1.7k total citations
42 papers, 1.2k citations indexed

About

Peter Winkle is a scholar working on Surgery, Anesthesiology and Pain Medicine and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Peter Winkle has authored 42 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Surgery, 7 papers in Anesthesiology and Pain Medicine and 7 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Peter Winkle's work include Anesthesia and Sedative Agents (5 papers), Anesthesia and Pain Management (4 papers) and Celiac Disease Research and Management (4 papers). Peter Winkle is often cited by papers focused on Anesthesia and Sedative Agents (5 papers), Anesthesia and Pain Management (4 papers) and Celiac Disease Research and Management (4 papers). Peter Winkle collaborates with scholars based in United States, Switzerland and Japan. Peter Winkle's co-authors include Keith M. Borkett, Daniel J. Pambianco, Howard I. Schwartz, Karin Wilhelm-Ogunbiyi, Dennis Riff, James P. Lees, Timothy Melson, Marija Pesic, Michel Struys and Joachim Ossig and has published in prestigious journals such as Gastroenterology, Antimicrobial Agents and Chemotherapy and Journal of Bone and Mineral Research.

In The Last Decade

Peter Winkle

41 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Winkle United States	18	434	355	214	140	132	42	1.2k
Rosanna Vaschetto Italy	28	373 0.9×	212 0.6×	718 3.4×	131 0.9×	17 0.1×	88	2.4k
Goda Choi Netherlands	21	233 0.5×	184 0.5×	474 2.2×	42 0.3×	20 0.2×	32	1.9k
Arthur C. Theodore United States	15	118 0.3×	122 0.3×	143 0.7×	129 0.9×	36 0.3×	26	1.4k
David Bernstein United States	22	103 0.2×	398 1.1×	96 0.4×	70 0.5×	31 0.2×	56	1.9k
Lucio Trevisani Italy	23	168 0.4×	793 2.2×	170 0.8×	180 1.3×	8 0.1×	77	1.5k
Michael Hofbeck Germany	28	141 0.3×	779 2.2×	196 0.9×	55 0.4×	86 0.7×	234	2.7k
Roberto Rech Italy	12	57 0.1×	218 0.6×	171 0.8×	171 1.2×	10 0.1×	26	1.3k
Andrew R L Medford United Kingdom	28	62 0.1×	358 1.0×	373 1.7×	114 0.8×	9 0.1×	125	2.4k
Josef Ben‐Ari Israel	18	67 0.2×	201 0.6×	56 0.3×	21 0.1×	17 0.1×	45	874
Fu‐Tsai Chung Taiwan	21	150 0.3×	305 0.9×	84 0.4×	440 3.1×	7 0.1×	89	1.8k

Countries citing papers authored by Peter Winkle

Since Specialization

Citations

This map shows the geographic impact of Peter Winkle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Winkle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Winkle more than expected).

Fields of papers citing papers by Peter Winkle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Winkle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Winkle. The network helps show where Peter Winkle may publish in the future.

Co-authorship network of co-authors of Peter Winkle

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Winkle. A scholar is included among the top collaborators of Peter Winkle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Winkle. Peter Winkle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Patel, Sanjay S., et al.. (2023). An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life. Human Vaccines & Immunotherapeutics. 19(2). 2254964–2254964. 20 indexed citations

Murray, Joseph A., Dina Wassaf, Karen Dunn, et al.. (2023). Safety and tolerability of KAN-101, a liver-targeted immune tolerance therapy, in patients with coeliac disease (ACeD): a phase 1 trial. The Lancet. Gastroenterology & hepatology. 8(8). 735–747. 34 indexed citations

Wiener, Gregory, et al.. (2023). A Phase 2 evaluation of a new flavored peg and sulfate solution compared to an over-the-counter laxative, peg and sports drink bowel preparation combination. BMC Gastroenterology. 23(1). 433–433. 1 indexed citations

Lefevre, Inge, Lulu Bravo, Nicolas Folschweiller, et al.. (2023). Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults. npj Vaccines. 8(1). 75–75. 8 indexed citations

Viscusi, Eugene R., Oscar A. de León-Casasola, Adam Jacobs, et al.. (2022). Celecoxib‐tramadol co‐crystal in patients with moderate‐to‐severe pain following bunionectomy with osteotomy: A phase 3, randomized, double‐blind, factorial, active‐ and placebo‐controlled trial. Pain Practice. 23(1). 8–22. 18 indexed citations

Stöhr, Thomas, Pieter Colin, Joachim Ossig, et al.. (2021). Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment. British Journal of Anaesthesia. 127(3). 415–423. 123 indexed citations

Singla, Neil, et al.. (2020). Opioid-free recovery after herniorrhaphy with HTX-011 as the foundation of a multimodal analgesic regimen. Surgery. 168(5). 915–920. 13 indexed citations

Viscusi, Eugene R., Harold S. Minkowitz, Peter Winkle, et al.. (2019). HTX-011 reduced pain intensity and opioid consumption versus bupivacaine HCl in herniorrhaphy: results from the phase 3 EPOCH 2 study. Hernia. 23(6). 1071–1080. 39 indexed citations

Yendewa, George A., J. McLeod Griffiss, Michael R. Jacobs, et al.. (2019). A two-part phase 1 study to establish and compare the safety and local tolerability of two nasal formulations of XF-73 for decolonisation of Staphylococcus aureus: A previously investigated 0.5 mg/g viscosified gel formulation versus a modified formulation. Journal of Global Antimicrobial Resistance. 21. 171–180. 14 indexed citations

10.

Fleischmann, R., Peter Winkle, Jeffrey N. Miner, et al.. (2018). Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study. RMD Open. 4(1). e000584–e000584. 37 indexed citations

11.

Fleischmann, Roy, Peter Winkle, Jesse Hall, et al.. (2018). Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study. RMD Open. 4(1). e000647–e000647. 11 indexed citations

12.

Banfield, Christopher, Matthew Scaramozza, Weidong Zhang, et al.. (2017). The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF‐06700841) in Healthy Subjects and Patients With Plaque Psoriasis. The Journal of Clinical Pharmacology. 58(4). 434–447. 71 indexed citations

13.

Glorieux, Francis H., Jean‐Pierre Devogelaer, Michaela Durigova, et al.. (2017). BPS804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial. Journal of Bone and Mineral Research. 32(7). 1496–1504. 107 indexed citations

14.

Pambianco, Daniel J., Keith M. Borkett, Dennis Riff, et al.. (2015). A phase IIb study comparing the safety and efficacy of remimazolam and midazolam in patients undergoing colonoscopy. Gastrointestinal Endoscopy. 83(5). 984–992. 125 indexed citations

15.

Chong, Edward, et al.. (2014). Drug–drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects. Journal of Nephrology. 27(6). 659–666. 20 indexed citations

16.

Borkett, Keith M., Dennis Riff, Howard I. Schwartz, et al.. (2014). A Phase IIa, Randomized, Double-Blind Study of Remimazolam (CNS 7056) Versus Midazolam for Sedation in Upper Gastrointestinal Endoscopy. Anesthesia & Analgesia. 120(4). 771–780. 153 indexed citations

17.

Drollmann, Anton, et al.. (2013). Glycopyrronium does not affect QT interval in healthy subjects: A randomized, 3-period cross-over, placebo- and positive-controlled study. European Respiratory Journal. 42(Suppl 57). 4634–4634.

18.

Samara, Emil, Peter Winkle, P. Gómez Pardo, et al.. (2013). Pharmacokinetics of dalfampridine extended release 7.5‐mg tablets in healthy subjects and individuals with mild and moderate renal impairment: An open‐label study. The Journal of Clinical Pharmacology. 54(1). 53–60. 6 indexed citations

19.

Bruce, R. Douglas, Peter Winkle, Joseph M. Custodio, et al.. (2013). The Pharmacokinetic and Pharmacodynamic Interactions Between Buprenorphine/Naloxone and Elvitegravir/Cobicistat in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment. JAIDS Journal of Acquired Immune Deficiency Syndromes. 63(4). 480–484. 14 indexed citations

20.

Jaros, Mark, et al.. (2012). Clinical evaluation of XaraColl®, a bupivacaine-collagen implant, for postoperative analgesia in two multicenter, randomized, double-blind, placebo-controlled pilot studies. Journal of Pain Research. 5. 217–217. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact